Human PDGFRA/CD140A/PDGFR2 ORF/cDNA clone-Adenovirus plasmid (BC015186)
Cat. No.: pGMAP000154
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human PDGFRA/CD140A/PDGFR2 adenoviral expression plasmid for PDGFRA adenovirus packaging, PDGFRA adenovirus.
Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.
Go to
PDGFR alpha/CD140a/PDGFRA/PDGFRA/CD140A products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
| Catalog ID | pGMAP000154 |
| Gene Name | PDGFRA |
| Accession Number | BC015186 |
| Gene ID | 5156 |
| Species | Human |
| Product Type | Adenovirus plasmid (overexpression) |
| Insert Length | 657 bp |
| Gene Alias | CD140A,PDGFR2 |
| Fluorescent Reporter | GFP |
| Mammalian Cell Selection | Null |
| Fusion Tag | 3xflag (C-Terminal) |
| Promoter | EF1 |
| Resistance | Kanamycin |
| ORF Nucleotide Sequence | ATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAGGGCTGAGCCTAATCCTCTGCCAGCTTTCATTACCCTCTATCCTTCCAAATGAAAATGAAAAGGTTGTGCAGCTGAATTCATCCTTTTCTCTGAGATGCTTTGGGGAGAGTGAAGTGAGCTGGCAGTACCCCATGTCTGAAGAAGAGAGCTCCGATGTGGAAATCAGAAATGAAGAAAACAACAGCGGCCTTTTTGTGACGGTCTTGGAAGTGAGCAGTGCCTCGGCGGCCCACACAGGGTTGTACACTTGCTATTACAACCACACTCAGACAGAAGAGAATGAGCTTGAAGGCAGGCACATTTACATCTATGTGCCAGACCCAGATGTAGCCTTTGTACCTCTAGGAATGACGGATTATTTAGTCATCGTGGAGGATGATGATTCTGCCATTATACCTTGTCGCACAACTGATCCCGAGACTCCTGTAACCTTACACAACAGTGAGGGGGTGGTACCTGCCTCCTACGACAGCAGACAGGGCTTTAATGGGACCTTCACTGTAGGGCCCTATATCTGTGAGGCCACCGTCAAAGGAAAGAAGTTCCAGACCATCCCATTTAATGTTTATGCTTTAAAAGGTACTTGTATCATCTCCTTCCTTCTTTAA |
| ORF Protein Sequence | MGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKGTCIISFLL |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
| Target ID | GM-T53524 |
| Target Name | PDGFR alpha/CD140a/PDGFRA |
|
Gene Group Identifier (Target Gene ID in Homo species) |
5156 |
| Gene ID |
100059815 (Equus caballus), 101090765 (Felis catus), 18595 (Mus musculus), 25267 (Rattus norvegicus) 282301 (Bos taurus), 442860 (Canis lupus familiaris), 5156 (Homo sapiens), 697002 (Macaca mulatta) |
| Gene Symbols & Synonyms | PDGFRA,Pdgfra,CD140a,Pdgfr-2,APDGFR,PDGFACE,CD140A,PDGFR2,PDGFR-2 |
| Target Alternative Names | APDGFR,Alpha platelet-derived growth factor receptor,Alpha-type platelet-derived growth factor receptor,CD140 antigen-like family member A,CD140A,CD140a,CD140a antigen,PDGF-R-alpha,PDGFACE,PDGFR alpha,PDGFR-2,PDGFR-alpha,PDGFR2,PDGFRA,Pdgfr-2,Pdgfra,Platelet-derived growth factor alpha receptor,Platelet-derived growth factor receptor 2 (PDGFR-2),Platelet-derived growth factor receptor alpha |
| Uniprot Accession |
P16234,P20786,P26618
Additional SwissProt Accessions: P26618,P20786,P16234 |
| Uniprot Entry Name | |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index, Cytokine Target |
| Disease | cancer, Non-Small Cell Lung Cancer |
| Disease from KEGG | EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer |
| Gene Ensembl | ENSECAG00000018176, ENSMUSG00000029231, ENSBTAG00000007173, ENSCAFG00845011775, ENSG00000134853, ENSMMUG00000017395 |
| Target Classification | Kinase |
About GMVC

GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.


